
Opinion|Videos|October 7, 2024
PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
2
FDA approves sildenafil oral film for men with erectile dysfunction
3
Sarah Azari, MD, on early sexual health education for women with bladder cancer
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5


